2023 World Conference on Lung Cancer (Posters)-P2.18. Real-world Study on Efficacy of First-Line Nivolumab + Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso)

P2.18. Real-world Study on Efficacy of First-Line Nivolumab + Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso) - PDF(Abstract)

Back to course

Pdf Summary

This document is a summary of a presentation titled "Real-world Study on Efficacy of First-Line Nivolumab Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso)" presented at the WCLC 2023 conference. The study aimed to evaluate the effectiveness of the combination of nivolumab and ipilimumab as a first-line treatment for unresectable malignant pleural mesothelioma (MPM) in a real-world setting.<br /><br />The study is a retrospective cohort analysis of patients with unresectable or metastatic MPM who were treated with the combination of nivolumab and ipilimumab in the first-line setting. The analysis included data from patients treated in seven different centers in Argentina and Colombia between June 2017 and January 2023.<br /><br />The study found that among the 50 patients included, 34% achieved an objective response, with 8% achieving a complete response and 26% achieving a partial response. The median progression-free survival (PFS) was 9 months, and the median overall survival (OS) was 30 months. There was no significant difference in PFS or OS between patients with epithelioid and non-epithelioid tumors. Patients who had an objective response had significantly better PFS and OS compared to those with disease stabilization.<br /><br />The study concluded that the combination of nivolumab and ipilimumab demonstrated substantial clinical efficacy and a survival benefit in the first-line treatment of patients with unresectable or metastatic MPM. The efficacy of this regimen was consistent regardless of histology. This study provides real-world evidence supporting the use of this treatment approach in this patient population.

Asset Subtitle

Edgar Aguirre

Meta Tag

Speaker Edgar Aguirre

Topic Mesothelioma, Thymoma & Other Thoracic Tumors: Clinical

Keywords

Real-world Study

Efficacy

First-Line

Nivolumab

Ipilimumab

Unresectable Malignant Pleural Mesothelioma

Objective Response

Progression-Free Survival

Overall Survival

Histology